Cell Death Differ:间充质干细胞移植技术揭示外泌体miR-21或可成为视网膜变性的潜在治疗靶标

2020-11-06 xiaozeng MedSci原创

感光细胞凋亡作为感光细胞死亡的主要形式之一,被认为是视网膜变性相关疾病的一种关键发病机制,其拮抗作用或可成为一种潜在的保护视觉功能的方法。

感光细胞凋亡作为感光细胞死亡的主要形式之一,被认为是视网膜变性相关疾病的一种关键发病机制,其拮抗作用或可成为一种潜在的保护视觉功能的方法。

既往研究显示,间充质干细胞移植(MSCT)在眼疾的治疗上具有巨大潜力,其中细胞外囊泡(EVs),特别是外泌体已成为有效的眼科治疗手段。然而,目前仍不清楚MSCT是否以及如何保护感光细胞免受细胞凋亡。因此,阐明相关的潜在作用和机制或可为视网膜变性相关疾病提供潜在的新疗法。


在该研究中,研究人员发现,在MNU(N-甲基-N-亚硝基脲)诱导感光细胞损伤的小鼠模型中,玻璃体内MSCT能够抵消光感受器的凋亡并减轻视网膜形态和功能上的退化。有趣的是,GW4869预处理能够通过阻断外泌体的生成抑制MSCT的作用。此外,MSC衍生的外泌体移植(EXOT)能够有效的抑制MNU诱发的感光细胞损伤。

玻璃体内MSCT能够抵消光感受器的凋亡并减轻视网膜病变

值得注意的是,MSCT和EXOT对MNU诱导的视网膜变性的治疗效果是持续性的,即使注射后1-2个月也能够检测到对感光细胞的保存和视网膜维持作用。更重要的是,Pde6bmut(Pde6b基因无义突变)引起的自然发生的视网膜变性模型中,研究人员证实,MSCT和EXOT可以防止感光细胞的丢失并长期保护视网膜的功能。


进一步的机制研究显示,miR-21能够通过靶向Pdcd4来维持抗MNU损伤的感光细胞的活性,并通过MSC衍生的外泌体进行转移以行使其功能调节作用。此外,缺乏miR-21会加重MNU诱发的视网膜损伤,这一作用受到EXOT的抑制。研究人员进一步证实,miR-21能够调节EXOT对MNU诱导的感光细胞凋亡和视网膜功能障碍的治疗作用。

外泌体miR-21能够抵消MNU诱导的感光细胞凋亡和视网膜变性

综上,该研究结果揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。


原始出处:

Deng, C., Hu, C., Ling, S. et al. Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration. Cell Death Differ (20 October 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
    2021-01-04 smallant2002
  3. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
    2020-11-14 isabellayj
  8. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
    2020-11-16 Nebula-Qin

    揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1815554, encodeId=779e1815554c6, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sun Jul 11 14:31:23 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930801, encodeId=1d6d193080186, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Jan 04 21:31:23 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703067, encodeId=1bff1e03067fa, content=<a href='/topic/show?id=1b871185e3a' target=_blank style='color:#2F92EE;'>#miR-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11857, encryptionId=1b871185e3a, topicName=miR-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bc730475489, createdName=dongjia2020, createdTime=Sat Jun 19 21:31:23 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747106, encodeId=4e431e471069d, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Thu Jun 10 08:31:23 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872042, encodeId=418218e20424d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 16 23:31:23 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1658952, encodeId=80451658952be, content=<a href='/topic/show?id=c40ce798412' target=_blank style='color:#2F92EE;'>#细胞移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77984, encryptionId=c40ce798412, topicName=细胞移植)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4724938298, createdName=limedical1982, createdTime=Thu Dec 10 17:31:23 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784228, encodeId=eebb1e84228e8, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Sat Nov 14 05:31:23 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909464, encodeId=37a11909464e6, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sat Apr 17 09:31:23 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899544, encodeId=d79c89954447, content=揭示了基于间充质干细胞移植(MSCT)的感光细胞保护机制,表明外泌体miR-21或可成为视网膜变性的一个潜在治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Mon Nov 16 09:58:04 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962344, encodeId=45b41962344b4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Sep 04 15:31:23 CST 2021, time=2021-09-04, status=1, ipAttribution=)]
    2021-09-04 维他命

相关资讯

Stem cells:口服抗生素破坏口腔微生物平衡,可损害牙龈间充质干细胞。

口腔微生物对维持口腔健康至关重要。口腔微生物失衡可导致牙周病和其他疾病。目前尚不知道口腔微生物是否会影响口腔干细胞的功能。本研究利用临床常见抗生素治疗方法改变口腔微生物的生态平衡,然后检测口腔间充质干细胞(MSCs)是否受影响。结果发现口腔微生物改变可导致牙龈MSCs缺陷,使得雄性小鼠的伤口延迟愈合。至于机制,口腔微生物可释放脂多糖(LPS),刺激microRNA-21(miR-21)表达,通过m

Diabetes:miR-21在糖尿病视网膜病变发病中的作用!

总之,糖尿病引起的视网膜miR-21过表达,至少部分负责DR中PPARα下调。靶向miR-21可能是DR的一种新治疗策略。

Nat Commun:外泌体miR-21或是治疗神经性疼痛的潜在靶点

在外周轴突损伤之后,背根神经节(DRG)的感觉神经元发生非编码microRNA(miRs)的失调。本研究中,研究人员发现DRG神经元细胞体在受刺激后可释放胞外囊泡,包括含有miRs的外泌体。研究人员发现,辣椒素激活TRPV1受体后,培养的DRG通过外泌体释放miR-21-5p。由辣椒素刺激的纯感觉神经元释放的外泌体容易被巨噬细胞吞噬,其中miR-21-5p表达的增加促进了促炎症表型。小鼠神经损伤后

PLoS One:miR-21的表达可预测乳腺癌患者的不良预后

背景:MicroRNA-21(miRNA-21和miR-21)可作为肿瘤的预后标志物。然而,现有的证据是有争议的。因此,目前的荟萃分析总结了这方面的证据,评估该基因在乳腺癌中的预后作用。方法:该荟萃分析是通过检索PubMed、EMBASE、科学网以及中国知网(CNKI)数据库进行的。数据是从调查miR-21的表达和乳腺癌患者的存活结果之间联系的研究中提取出来的。关于生存结果,统计miR-21的危险

Indian J Urol:MicroRNA-21可作为预测非肌肉侵入性膀胱癌复发的分子标记

非肌肉侵入性膀胱癌(NMIBC)的高复发率到目前为止还是一个巨大的挑战。 microRNA-21(miR-21)的超表达在膀胱肿瘤组织和正常粘膜的比较已经有所报道,并且miR-21能以与恶性肿瘤相关的磷酸酶和张力蛋白同源体基因(PTEN)为靶标。最近,有研究人员测试了是否miR-21在膀胱粘膜中的水平可以预测肿瘤复发。在一个前瞻性的群体研究中,研究人员在经尿道膀胱肿瘤切除术中从BC病人中获取了肿瘤

CCR:微RNA表达异常降低胰腺导管腺癌(PDAC)患者生存率

 《临床癌症研究》杂志11月23日在线发表的一项研究表明,胰腺导管腺癌(PDAC)组织微RNA(miR)的表达显著改变。一些miR的异常表达,包括miR-21过度表达和miR-34a表达不足与患者生存率下降独立相关。   该研究分析了48例胰腺导管腺癌组织中miR表达情况,评估了其与肿瘤分期、淋巴结状态和复发部位的关联,并在另外24例患者中,验证了经挑选的可能的具有预后意义的miR。   结果